Affibody's albumin binding technology will be applied in some of our targeted therapeutics programs and is also offered to other biotech and pharmaceutical companies as a stand-alone licensing opportunity.

The technology provides the fusion partner with an extended half-life in vivo

The albumin binding domain (ABD) is a small (5 kDa) compact single-domain protein with high affinity binding to serum albumin, which is readily made into a fusion protein with Affibody® molecules or other biopharmaceutical proteins.